Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  bendamustine hydrochloride
Find trials that include:  Any drugs shown
Results 1-25 of 35 for your search:
Start Over
Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients with Previously Untreated Chronic Lymphocytic Leukemia
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 65 and over
Trial IDs: A041202, NCI-2013-01220, ALLIANCE A041202, NCT01886872
Bendamustine in Combination With Bortezomib and Pegylated Liposomal Doxorubicin for Multiple Myeloma
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: MM08-141, NCI-2012-00848, NCT01177683
Bendamustine Hydrochloride, Ofatumumab, Carboplatin, and Etoposide in Treating Patients with Relapsed or Refractory Aggressive B-Cell Lymphoma
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 11D.404, NCI-2011-03434, 2011-61, NCT01458366
Bendamustine Hydrochloride, Rituximab, and Pixantrone Dimaleate in Treating Patients with Relapsed or Refractory B Cell Non-Hodgkin Lymphoma
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: Pro00030834, NCI-2013-02201, NCI-2012-00398, NCT01491841
Gemcitabine Hydrochloride and Bendamustine Hydrochloride in Patients With Relapsed or Refractory Hodgkin Lymphoma
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: OSU-11015, NCI-2012-00022, 2011C0105, NCT01535924
Brentuximab Vedotin and Bendamustine Hydrochloride in Treating Patients with Relapsed or Refractory Hodgkin Lymphoma or Anaplastic Large Cell Lymphoma
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: AAAJ5050, NCI-2012-01926, NCT01657331
Bendamustine Hydrochloride, Pomalidomide, and Dexamethasone in Treating Patients with Relapsed or Refractory Multiple Myeloma
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: Pro00040206, NCI-2013-00480, MM-PI-0045, PO-MM-PI-0045, NCT01754402
Carfilzomib in Combination with Bendamustine Hydrochloride and Dexamethasone in Treating Patients with Newly Diagnosed Multiple Myeloma
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: AAAJ2359, NCI-2014-02521, IRB-AAAJ2359, NCT02002598
Bendamustine Hydrochloride in Treating Patients with Recurrent or Progressive Anaplastic Glioma
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 6803, NCI-2010-00714, UWCC-6803, FHCRC-6803, IR-6803, NCCN-C01, NCT00823797
Rituximab and Pentostatin or Bendamustine Hydrochloride in Treating Patients with Relapsed or Refractory Hairy Cell Leukemia
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 10-C-0025, NCI-2013-01455, P09576, NCT01059786
Bendamustine Hydrochloride and Rituximab in Treating Older Patients With Previously Untreated Stage II-IV Diffuse Large B-cell Lymphoma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 65 and over
Trial IDs: LCCC 1011, NCI-2013-01040, NCT01234467
Ofatumumab and Bendamustine Hydrochloride with or without Bortezomib in Treating Patients with Untreated Follicular Non-Hodgkin Lymphoma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CALGB 50904, NCI-2011-02625, CDR0000694298, NCT01286272
Ofatumumab and Bendamustine Followed by Maintenance Ofatumumab for Rituximab Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (B-NHL)
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 114612, NCI-2011-01815, OFB114612, NCT01294579
Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Patients with Previously Untreated Mantle Cell Lymphoma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Supportive care, Treatment
Age: 60 and over
Trial IDs: E1411, NCI-2011-02980, CDR0000707057, ECOG-E1411, NCT01415752
Bendamustine Hydrochloride and Rituximab Followed by Rituximab and Lenalidomide in Treating Patients with Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: HO11414, NCI-2013-00485, 2012-0638, 2012-0638-CP008, 2012-0638-CR003, ML28201, RV-CLL/ -PI-0689, NCT01754857
Bendamustine Hydrochloride, Bortezomib, and Dexamethasone in Treating Patients with Newly Diagnosed Multiple Myeloma
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 14D.300, NCI-2014-01771, 2014-025, 6192, NCT02224729
A Study of Polatuzumab Vedotin (DCDS4501A) in Combination With Rituximab or Obinutuzumab Plus Bendamustine in Patients With Relapsed or Refractory Follicular or Diffuse Large B-Cell Lymphoma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: GO29365, NCI-2015-00293, 2014-001361-28, NCT02257567
Bendamustine Hydrochloride, Obinutuzumab, and Dexamethasone in Treating Older Patients with Diffuse Large B-cell Lymphoma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 70 and over
Trial IDs: IRB14-1120, NCI-2015-00355, NCT02420210
Bendamustine Hydrochloride, Pentostatin, and Ofatumumab in Treating Patients with Previously Treated Chronic Lymphocytic Leukemia or Non-Hodgkin Lymphoma
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 11P.166, NCI-2011-02341, 2011-23, NCT01352312
Lenalidomide, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 11-016, NCI-2011-03689, RV CLL-PI-0613, NCT01400685
Start Over